Selin Ocal1, Andrew J Muir2. 1. Duke University, Durham, NC, USA. selin.ocal@duke.edu. 2. Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Abstract
PURPOSE OF REVIEW: The prevalence of Hepatitis C virus (HCV) in the US incarcerated population is disproportionately high, and when inmates with infection are released back into the general population, they play a substantial role in the spread of disease. This review provides support for targeting the jail/prison population to eliminate HCV in the general population. It will also summarize various screening/treatment models to curtail the burden of disease behind and beyond bars. RECENT FINDINGS: Transitioning from risk-based testing to opt-out testing in prisons/jails would be cost-effective through greater identification of cases and treatment to prevent complications from cirrhosis. Other innovative strategies, such as the nominal pricing mechanism or the "Netflix" DAA subscription model, have the potential to be cost-effective and to increase access to treatment. Addressing HCV in the incarcerated population is a strategy to bring the US closer to successfully eradicating the epidemic. Such findings should incentivize policymakers to implement care models that target this population.
PURPOSE OF REVIEW: The prevalence of Hepatitis C virus (HCV) in the US incarcerated population is disproportionately high, and when inmates with infection are released back into the general population, they play a substantial role in the spread of disease. This review provides support for targeting the jail/prison population to eliminate HCV in the general population. It will also summarize various screening/treatment models to curtail the burden of disease behind and beyond bars. RECENT FINDINGS: Transitioning from risk-based testing to opt-out testing in prisons/jails would be cost-effective through greater identification of cases and treatment to prevent complications from cirrhosis. Other innovative strategies, such as the nominal pricing mechanism or the "Netflix" DAA subscription model, have the potential to be cost-effective and to increase access to treatment. Addressing HCV in the incarcerated population is a strategy to bring the US closer to successfully eradicating the epidemic. Such findings should incentivize policymakers to implement care models that target this population.
Entities:
Keywords:
Correctional system; HCV elimination; HCV testing and treatment; Hepatitis C virus; Incarcerated population; Opt-out testing
Authors: Anne C Spaulding; Jagpreet Chhatwal; Madeline G Adee; Robert T Lawrence; Curt G Beckwith; William von Oehsen Journal: J Correct Health Care Date: 2018-10-15
Authors: Amy L Althoff; Alexei Zelenev; Jaimie P Meyer; Jeannia Fu; Shan-Estelle Brown; Panagiotis Vagenas; Ann K Avery; Jacqueline Cruzado-Quiñones; Anne C Spaulding; Frederick L Altice Journal: AIDS Behav Date: 2013-10
Authors: Sarah Larney; Hannah Kopinski; Curt G Beckwith; Nickolas D Zaller; Don Des Jarlais; Holly Hagan; Josiah D Rich; Brenda J van den Bergh; Louisa Degenhardt Journal: Hepatology Date: 2013-08-06 Impact factor: 17.425
Authors: Natasha K Martin; Peter Vickerman; Iain F Brew; Joan Williamson; Alec Miners; William L Irving; Sushma Saksena; Sharon J Hutchinson; Sema Mandal; Eamonn O'Moore; Matthew Hickman Journal: Hepatology Date: 2016-03-22 Impact factor: 17.425
Authors: Eli S Rosenberg; Elizabeth M Rosenthal; Eric W Hall; Laurie Barker; Megan G Hofmeister; Patrick S Sullivan; Patricia Dietz; Jonathan Mermin; A Blythe Ryerson Journal: JAMA Netw Open Date: 2018-12-07
Authors: Klára Werling; Béla Hunyady; Mihály Makara; Krisztina Nemesi; Gábor Horváth; Ferenc Schneider; Judit Enyedi; Zsófia Müller; Miklós Lesch; Zoltán Péterfi; Tamás Tóth; Judit Gács; Zsuzsanna Fehér; Eszter Ujhelyi; Emese Molnár; Anna Nemes Nagy Journal: Viruses Date: 2022-02-02 Impact factor: 5.048